$Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR$

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

10.1038/leu.2016.390

Saved in:

Bibliographic Details
Main Authors:	Chng, W-J, Goldschmidt, H, Dimopoulos, MA, Moreau, P, Joshua, D, Palumbo, A, Facon, T, Ludwig, H, Pour, L, Niesvizky, R, Oriol, A, Rosinol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Gillenwater, HH, Mohamed, N, Feng, S, Aggarwal, S, Hajek, R
Other Authors:	DEAN'S OFFICE (MEDICINE)
Format:	Article
Language:	English
Published:	NATURE PUBLISHING GROUP 2022
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology Hematology LOW-DOSE DEXAMETHASONE STEM-CELL TRANSPLANTATION PLUS DEXAMETHASONE INTERGROUPE FRANCOPHONE DELETION 17P LENALIDOMIDE THERAPY ABNORMALITIES POMALIDOMIDE THALIDOMIDE
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/229014
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

id	sg-nus-scholar.10635-229014
record_format	dspace
spelling	sg-nus-scholar.10635-2290142024-11-09T01:52:06Z Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR Chng, W-J Goldschmidt, H Dimopoulos, MA Moreau, P Joshua, D Palumbo, A Facon, T Ludwig, H Pour, L Niesvizky, R Oriol, A Rosinol, L Suvorov, A Gaidano, G Pika, T Weisel, K Goranova-Marinova, V Gillenwater, HH Mohamed, N Feng, S Aggarwal, S Hajek, R DEAN'S OFFICE (MEDICINE) Prof Wee Joo Chng Science & Technology Life Sciences & Biomedicine Oncology Hematology LOW-DOSE DEXAMETHASONE STEM-CELL TRANSPLANTATION PLUS DEXAMETHASONE INTERGROUPE FRANCOPHONE DELETION 17P LENALIDOMIDE THERAPY ABNORMALITIES POMALIDOMIDE THALIDOMIDE 10.1038/leu.2016.390 LEUKEMIA 31 6 1368-1374 2022-07-21T07:17:04Z 2022-07-21T07:17:04Z 2017-06-01 2022-07-17T12:13:36Z Article Chng, W-J, Goldschmidt, H, Dimopoulos, MA, Moreau, P, Joshua, D, Palumbo, A, Facon, T, Ludwig, H, Pour, L, Niesvizky, R, Oriol, A, Rosinol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Gillenwater, HH, Mohamed, N, Feng, S, Aggarwal, S, Hajek, R (2017-06-01). Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. LEUKEMIA 31 (6) : 1368-1374. ScholarBank@NUS Repository. https://doi.org/10.1038/leu.2016.390 08876924 14765551 https://scholarbank.nus.edu.sg/handle/10635/229014 en NATURE PUBLISHING GROUP Elements
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
language	English
topic	Science & Technology Life Sciences & Biomedicine Oncology Hematology LOW-DOSE DEXAMETHASONE STEM-CELL TRANSPLANTATION PLUS DEXAMETHASONE INTERGROUPE FRANCOPHONE DELETION 17P LENALIDOMIDE THERAPY ABNORMALITIES POMALIDOMIDE THALIDOMIDE
spellingShingle	Science & Technology Life Sciences & Biomedicine Oncology Hematology LOW-DOSE DEXAMETHASONE STEM-CELL TRANSPLANTATION PLUS DEXAMETHASONE INTERGROUPE FRANCOPHONE DELETION 17P LENALIDOMIDE THERAPY ABNORMALITIES POMALIDOMIDE THALIDOMIDE Chng, W-J Goldschmidt, H Dimopoulos, MA Moreau, P Joshua, D Palumbo, A Facon, T Ludwig, H Pour, L Niesvizky, R Oriol, A Rosinol, L Suvorov, A Gaidano, G Pika, T Weisel, K Goranova-Marinova, V Gillenwater, HH Mohamed, N Feng, S Aggarwal, S Hajek, R Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
description	10.1038/leu.2016.390
author2	DEAN'S OFFICE (MEDICINE)
author_facet	DEAN'S OFFICE (MEDICINE) Chng, W-J Goldschmidt, H Dimopoulos, MA Moreau, P Joshua, D Palumbo, A Facon, T Ludwig, H Pour, L Niesvizky, R Oriol, A Rosinol, L Suvorov, A Gaidano, G Pika, T Weisel, K Goranova-Marinova, V Gillenwater, HH Mohamed, N Feng, S Aggarwal, S Hajek, R
format	Article
author	Chng, W-J Goldschmidt, H Dimopoulos, MA Moreau, P Joshua, D Palumbo, A Facon, T Ludwig, H Pour, L Niesvizky, R Oriol, A Rosinol, L Suvorov, A Gaidano, G Pika, T Weisel, K Goranova-Marinova, V Gillenwater, HH Mohamed, N Feng, S Aggarwal, S Hajek, R
author_sort	Chng, W-J
title	Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
title_short	Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
title_full	Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
title_fullStr	Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
title_full_unstemmed	Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
title_sort	carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study endeavor
publisher	NATURE PUBLISHING GROUP
publishDate	2022
url	https://scholarbank.nus.edu.sg/handle/10635/229014
_version_	1821185228451872768

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

Similar Items